APOE ε4 carriage is associated with pallido-putaminal diffusion alterations in early Parkinson’s disease
This study reveals that APOE ε4 carriers with early, drug-naïve Parkinson's disease exhibit specific microstructural alterations in the pallido-putaminal regions compared to non-carriers, suggesting a link between this genetic risk factor and distinct neural changes in the disease's initial stages.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Parkinson's disease is a condition that slowly disrupts the brain's ability to control movement, but it is far more than a simple motor problem. It is a complex disorder where the brain's cells gradually break down, often leading to memory loss and other non-movement issues. Scientists have long known that a person's genes play a role in how the disease starts and how quickly it progresses. One specific gene, called APOE, is famous for its connection to Alzheimer's disease; carrying a particular version of this gene, known as the epsilon-4 variant, significantly increases the risk of developing Alzheimer's. However, its role in Parkinson's has been murkier. While it does not seem to cause Parkinson's itself, evidence suggests it might act like a modifier, changing how the disease behaves in those who already have it. To understand this, researchers look at the brain's microscopic structure. They use a special type of magnetic resonance imaging that tracks how water moves through brain tissue. If the tissue is healthy and tightly organized, water moves in a specific direction. If the tissue is damaged or losing its structure, water moves more freely and chaotically. This movement acts as a subtle signal of what is happening inside the brain long before large-scale damage becomes visible on standard scans.
A team of researchers at the IRCCS Centro Neurolesi in Italy set out to investigate whether this specific gene variant changes the microscopic structure of the brain in the very early stages of Parkinson's. They studied a group of people who had just been diagnosed with the disease and had not yet started taking medication, ensuring that their brain scans reflected the disease itself rather than the effects of treatment. They compared these patients to a group of healthy individuals, looking specifically at those who carried the epsilon-4 gene variant against those who did not. The scientists focused on the deep centers of the brain responsible for movement, known as the basal ganglia, which include structures like the pallidum and the putamen. They wanted to see if the gene variant left a unique fingerprint on the brain's microstructure that could be detected before the disease caused significant shrinkage or volume loss.
The study involved 121 people in total: 75 patients with early Parkinson's and 46 healthy controls. Within the patient group, 25 people carried the epsilon-4 variant, while the rest did not. The researchers used advanced imaging to measure how water moved through the brain tissue. They found a clear difference in the patients with Parkinson's who carried the gene. In the deep brain structures that control movement, the water movement patterns were altered in a way that suggested the tissue was less organized. Specifically, the water moved more freely in directions that usually indicate a loss of structural integrity. This was most noticeable in the pallidum and the putamen on the left side of the brain. In contrast, the healthy people who carried the same gene variant showed no such changes. Their brain tissue looked just like the tissue of healthy people without the gene. This is a crucial finding because it suggests that the gene's effect is specific to the disease environment; it does not seem to damage the brain on its own in people who are healthy, but it interacts with Parkinson's to create these early microscopic changes.
The researchers also looked to see if these tiny changes in water movement were linked to other signs of the disease. They found that in the patients, the areas where water moved more freely were associated with higher levels of a protein in the blood called neurofilament light chain. This protein is a known marker for nerve damage; when nerve cells are injured, this protein leaks into the bloodstream. The connection suggests that the gene variant might be linked to a faster or more intense process of nerve damage in these specific brain regions. However, the study did not find that the gene variant caused the damage to get worse faster over time in the way they had hoped to prove. The link was present at the start, but it did not predict a steeper decline over the next two years. Furthermore, the researchers checked for physical shrinkage of the brain areas and found none. The changes were purely microscopic, happening at a level of organization that standard scans cannot see.
Beyond the brain scans, the team tracked how the patients felt and performed over several years. They noticed that patients with the gene variant reported more difficulty with their daily activities, such as walking or dressing, compared to those without the gene. This was a subjective measure of how the disease affected their lives, rather than a score from a doctor's exam. They also saw that levels of a protein related to Alzheimer's pathology in the spinal fluid rose more quickly in the gene carriers over four years. Interestingly, there was a temporary boost in memory performance for the gene carriers at the two-year mark, but this did not last. These findings hint that the gene might influence how the disease feels to the patient and how certain biological markers change, but the link to the brain's microscopic structure remains the most solid discovery.
The study concludes that carrying the epsilon-4 gene variant in early Parkinson's disease is associated with specific, subtle changes in the brain's deep movement centers. These changes are visible through advanced imaging as a disruption in how water moves through the tissue, indicating a loss of structural order. This happens without the brain shrinking, suggesting the damage is happening at a cellular level before the tissue is lost. While the gene does not appear to cause these changes in healthy people, it seems to leave a distinct mark on the brains of those with Parkinson's. The researchers emphasize that while these findings are promising, they need to be confirmed with larger groups of people and repeated scans over time to understand if these early signs can predict who will get sicker faster. For now, the work provides a clearer picture of how genetics and the disease interact at the very beginning of the journey, offering a potential new way to look at the brain that goes beyond what the naked eye can see.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.